Investor Information
Analyst Coverage
SXC Health Solutions, Inc. is followed by the analysts listed below.
Please note that any opinions, estimates or forecasts regarding SXC Health Solutions, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of SXC Health Solutions, Inc.
- Analyst
- Firm
- City
- Blair Abernethy
- Thomas Weisel
- Toronto
- Michael J. Baker
- Raymond James & Associates, Inc
- Florida
- Glenn Garmont
- ThinkEquity LLC
- New York
- Alex Grassino
- Laurentian Bank
- Montreal
- Donald Hooker
- UBS
- New York
- Glenn Jamieson
- Maquarie Capital Markets Canada Ltd.
- Toronto
- Husein Kirefu
- M Partners
- Toronto
- Gabriel Leung
- Paradigm Capital
- Toronto
- Tom Liston
- Versant Partners
- Toronto
- David MacDonald
- SunTrust Robinson Humphrey
- Boston
- Michael Minchak
- JP Morgan
- New York
- Brooks O’Neil
- Dougherty & Co.
- Minneapolis
- Tony Perkins
- First Analysis
- Chicago
- Charles Rhyee
- Oppenheimer & Company
- New York
- Paul Steep
- Scotia Capital
- Toronto
- Richard Tse
- National Bank Financial
- Toronto
Additional Links Here
Valued Partnerships
"Department of Health and Human Services projects U.S. prescription drug spending to increase from $200.7 billion in 2005 to $497.5 billion in 2016, a 148% increase in 11 years."– Kaiser Family
Foundation – Prescription Drug
Trends Fact Sheet,
May 2007
Fusce semper lorem quis sem viverra sagittis fermentum est fermentum. Maecenas ligula sapien, fringilla nec tincidunt at, mollis vitae tortor.
3/5/10 usce semper lorem
4/6/10 Quis sem viverra sagittis fermentum
5/16/10 st fermentum maecenas ligula sapien
6/20/10 Fringilla nec tincidunt at mollis
7/1/10 Quis sem viverra sagittis fermentum
4/6/10 Quis sem viverra sagittis fermentum
5/16/10 st fermentum maecenas ligula sapien
6/20/10 Fringilla nec tincidunt at mollis
7/1/10 Quis sem viverra sagittis fermentum
